Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
AstraZeneca ( (GB:AZN) ) has shared an update.
AstraZeneca and Daiichi Sankyo have withdrawn their EU marketing application for datopotamab deruxtecan for advanced nonsquamous non-small cell lung cancer following feedback from the European Medicines Agency. Despite this, they remain committed to advancing this treatment through ongoing clinical trials and are continuing to pursue its potential in various lung cancer settings. The withdrawal highlights the challenges in bringing new cancer therapies to market and underscores the companies’ resilience in exploring further development opportunities for this investigational drug.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, specializing in the discovery, development, and commercialization of prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals. The company’s products are available in over 125 countries, serving millions of patients worldwide.
YTD Price Performance: -1.12%
Average Trading Volume: 2,667,942
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £159B
See more data about AZN stock on TipRanks’ Stock Analysis page.
